The company has highlighted the study as evidence that its test would outperform Roche's FDA-approved liquid biopsy assay if implemented in the clinic.
The company will design and validate a test using its Exolution isolation kit, which can stratify and monitor patients in Intezyne's clinical trials of IT-139.
Based on technology developed at Mass General, the platform will allow the company and its customers to add protein detection to nucleic acid analysis.
The coverage decision is based on the results of an evidence development study the companies launched last year.
A research collaboration involving several universities has yielded a technique that they said isolates exosomes from biological samples more effectively than incumbent methods.
The study is part of an effort to drive health plan coverage for Exosome's ExoDx Prostate IntelliScore prostate cancer test.
The partners will collaborate on clinical studies aimed at driving health plan coverage for molecular diagnostic products.
The funds will support a variety of business activities including diagnostic test development and the advance of new methods for tissue-specific exosome isolation.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.